Article
Gilead to Acquire Myogen
Author(s):
Gilead Sciences, of Foster City, CA (www.gilad.com), has agreed to acquire Myogen for about $2.5 billion, a move aimed at gaining ownership of Ambrisentan, a treatment for pulmonary arterial hypertension that is in late-stage clinical trials.
Gilead Sciences, of Foster City, CA (www.gilad.com), has agreed to acquire Myogen for about $2.5 billion, a move aimed at gaining ownership of Ambrisentan, a treatment for pulmonary arterial hypertension that is in late-stage clinical trials. The drug is Myogen’s lead product candidate. Myogen expects to file a new-drug application for Ambrisentan with the FDA as early as the fourth quarter. British drug maker GlaxoSmithKline holds rights to the product outside of the US.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
